A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
70actual
Sites
16
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-23 | actual | When the study began enrolling |
| Primary completion | 2024-09-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Thyroid Neoplasms
Intervention
- Drug: LOXO-260 — also filed as LY3838915
Primary outcome
what the primary-completion date above is the date OFPhase 1 a: To determine the MTD/RP2D of LOXO-260: Dose limiting toxicity (DLT) rate
measured During the first 28-day cycle of LOXO-260 treatment
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed